Value on Survival Prediction of The Changes of AFP and sICAM-1 Before and after Surgical Treatment of Hepatocellular Carcinoma_CHINESE JOURNAL OF BASES AND CLINICS IN GENERAL SURGERY

Authors：

 CHENYu ^1,2 , CAODa-yong ¹ ,  LIXiao ¹

1. Department of Hepatobiliary Surgery, Xijing Hospital, The Forth Military Medical University, Xi'an 710032, Shaanxi Province, China;
2. Department of General Surgery, No. 451 Hospital of PLA, Xi'an 710054, Shaanxi Province, China;

Corresponding?author：

LIXiao, Email: lixiao0076@163.com

Keywords：

Primary hepatocellular carcinoma; α-fetoprotein; Soluble cell adhesion molecule-1; Survival analysis

DOI：

10.7507/1007-9424.20140198

Video：

Export PDF Favorites Scan Get Citation

Abstract Full text Figures/Tables Video References Cited by

Objective To study the clinical value of changes of serumα-fetoprotein(AFP) and soluble cell adhesion molecule-1(sICAM-1) levels before and after surgical treatment of primary hepatocellular carcinoma(PHC) as predictors of patient survival. Methods The clinical data and followed-up results of 86 patients with hepatocellular carcinoma received hepatectomy or radiofrequency ablation(RFA) in Xijing Hospital and the 451^st Hospital of PLA were retrospectivly analyzed. The changes of peripheral blood AFP and sICAM-1 levels in patients before and in 1 month after treatment were observed and all patients were divided into different groups according to the changes in both two markers. Then survival rates of each group were analyzed. Results The patients with AFP < 20μg/L or sICAM-1 < 1 000 U/L before treatment had lower tumor recurrence rate and higher survival rate than patients with elevated serum levels of the both markers(AFP:P=0.018, P < 0.001;sICAM-1:P=0.027, P < 0.001). The larger tumor, late TNM stage, and higher rate of recurrence were associated with elevated serum levels of the both markers(AFP:P=0.016, P=0.026 and P=0.025;sICAM-1:P < 0.001, P=0.024 and P=0.032). The better survival situation was closely related with these cases treated with hepatectomy and their levels of both markers were lower than the above cutoff values both before and after treatment, or leves of both markers above the cut-off values returned to within the normal range after treatment (AFP:P=0.006, P=0.001;sICAM-1:P=0.001, P=0.002). The patients who had simultaneous increase of AFP and sICAM-1 after operation showed the worst tumor-free and overall survivals(P=0.007, P < 0.001). Conclusion To test the changes of serum AFP and sICAM-1 levels in early stage after treatment for patients who received radical resection of hepatocellular carcinoma has good clinical value for monitoring of tumor recurrence and predict prognosis.

Citation： CHENYu, CAODa-yong, LIXiao. Value on Survival Prediction of The Changes of AFP and sICAM-1 Before and after Surgical Treatment of Hepatocellular Carcinoma. CHINESE JOURNAL OF BASES AND CLINICS IN GENERAL SURGERY, 2014, 21(7): 832-840. doi: 10.7507/1007-9424.20140198 Copy

1.	?Guiu B, Minello A, Cottet V, et al. A 30-year, population-based study shows improved management and prognosis of hepatocellular carcinoma[J]. Clin Gastroenterol Hepatol, 2010, 8(11):986-991.
2.	Nordenstedt H, White DL, El-Serag HB. The changing pattern of epidemiology in hepatocellular carcinoma[J]. Dig Liver Dis, 2010, 42(Suppl 3):S206-S214.
3.	Jemal A, Bray F, Center MM, et al. Global cancer statistics, 2011[J]. CA Cancer J Clin, 2011, 61(2):69-90.
4.	戴朝六, 趙陽.原發性肝癌的綜合治療[J].中國普外基礎與臨床雜志, 2014, 21(2):133-137.
5.	許磊波, 王捷, 劉超.不同分期系統對晚期肝癌肝切除患者生存的預測價值比較[J].中國普外基礎與臨床雜志, 2014, 21(2):138-141.
6.	Moriya S, Morimoto M, Numata K, et al. Fucosylated fraction of alpha-fetoprotein as a serological marker of early hepatocellular carcinoma[J]. Anticancer Res, 2013, 33(3):997-1001.
7.	Ertle JM, Heider D, Wichert M, et al. A combination ofα-feto-protein and des-γ-carboxy prothrombin is superior in detection of hepatocellular carcinoma[J]. Digestion, 2013, 87(2):121-131.
8.	El-Serag HB, Kanwal F.α-Fetoprotein in hepatocellular carcinoma surveillance:mend it but do not end it[J]. Clin Gastroenterol Hepatol, 2013, 11(4):441-443.
9.	Helaly GF, Abou Shamaa LA. Influence of hepatitis C virus infection on circulating levels of sICAM-1 and VEGF in patients with hepatitis C and hepatocellular carcinoma (HCC) and their role in enhancing detection of HCC[J]. Egypt J Immunol, 2006, 13(1):27-38.
10.	Nakano M, Ando E, Kuromatsu R, et al. Recent progress in the management of hepatocellular carcinoma detected during a surveillance program in Japan[J]. Hepatol Res, 2010, 40(10): 989-996.
11.	趙威, 竇科峰, 岳樹強, 等.外周血sICAM-1聯合AFP檢測對原發性肝癌診斷的意義[J].中華實用診斷與治療雜志, 2008, 22(7):481-482.
12.	Zhu XW, Gong JP. Expression and role of icam-1 in the occurrence and development of hepatocellular carcinoma[J]. Asian Pac J Cancer Prev, 2013, 14(3):1579-1583.
13.	Liu S, Li N, Yu X, et al. Expression of intercellular adhesion molecule 1 by hepatocellular carcinoma stem cells and circulating tumor cells[J]. Gastroenterology, 2013, 144(5):1031-1041.
14.	Zhao YJ, Ju Q, Li GC. Tumor markers for hepatocellular carcinoma[J]. Mol Clin Oncol, 2013, 1(4):593-598.
15.	Wu J, Zou H, Jiang JT, et al. Clinical application of serum alpha-fetoprotein-IgM complexes on the diagnosis of primary hepatocellular carcinoma in Kazakh and Han populations[J]. Tumori, 2013, 99(4):535-539.
16.	Nakazawa T, Hidaka H, Takada J, et al. Early increase inα-fetoprotein for predicting unfavorable clinical outcomes in patients with advanced hepatocellular carcinoma treated with sorafenib[J]. Eur J Gastroenterol Hepatol, 2013, 25(6):683-689.
17.	蘇志良, 趙浩亮, 曹燕, 等.大鼠離體肝臟保存再灌注后肝臟中ICAM-1 mRNA的表達及丹參對其表達的影響[J].中國普外基礎與臨床雜志, 2013, 20(8):932-933.
18.	Long EO. ICAM-1:getting a grip on leukocyte adhesion[J]. J Immunol, 2011, 186(9):5021-5023.
19.	Xiao X, Mruk DD, Cheng CY. Intercellular adhesion molecules (ICAMs) and spermatogenesis[J]. Hum Reprod Update, 2013, 19(2):167-186.
20.	Schmitz V, Sauerbruch T, Raskopf E. Anti-tumoural effects of PlgK1-5 are directly linked to reduced ICAM expression, resulting in hepatoma cell apoptosis[J]. Int J Colorectal Dis, 2012, 27(8): 1029-1038.
21.	Jung CW, Song TJ, Lee KO, et al. Characterization of hepatocellular carcinoma cell lines based on cell adhesion molecules[J]. Int J Mol Med, 2012, 29(6):1158-1164.
22.	Qin LX, Tang ZY. Recent progress in predictive biomarkers for metastatic recurrence of human hepatocellular carcinoma:a review of the literature[J]. J Cancer Res Clin Oncol, 2004, 130(9): 497-513.
23.	Kamezaki S, Kurozawa Y, Iwai N, et al. Serum levels of soluble ICAM-1 and VCAM-1 predict pre-clinical cancer[J]. Eur J Cancer, 2005, 41(15):2355-2359.
24.	Sun JJ, Zhou XD, Zhou G, et al. Expression of intercellular adhesive molecule-1 in liver cancer tissues andliver cancer metastasis[J]. World J Gastroenterol, 1998, 4(3):202-205.
25.	Sarwar S, Khan AA, Tarique S. Validity of alpha fetoprotein for diagnosis of hepatocellular carcinoma in cirrhosis[J]. J Coll Physicians Surg Pak, 2014, 24(1):18-22.

1. ?Guiu B, Minello A, Cottet V, et al. A 30-year, population-based study shows improved management and prognosis of hepatocellular carcinoma[J]. Clin Gastroenterol Hepatol, 2010, 8(11):986-991.
2. Nordenstedt H, White DL, El-Serag HB. The changing pattern of epidemiology in hepatocellular carcinoma[J]. Dig Liver Dis, 2010, 42(Suppl 3):S206-S214.
3. Jemal A, Bray F, Center MM, et al. Global cancer statistics, 2011[J]. CA Cancer J Clin, 2011, 61(2):69-90.
4. 戴朝六, 趙陽.原發性肝癌的綜合治療[J].中國普外基礎與臨床雜志, 2014, 21(2):133-137.
5. 許磊波, 王捷, 劉超.不同分期系統對晚期肝癌肝切除患者生存的預測價值比較[J].中國普外基礎與臨床雜志, 2014, 21(2):138-141.
6. Moriya S, Morimoto M, Numata K, et al. Fucosylated fraction of alpha-fetoprotein as a serological marker of early hepatocellular carcinoma[J]. Anticancer Res, 2013, 33(3):997-1001.
7. Ertle JM, Heider D, Wichert M, et al. A combination ofα-feto-protein and des-γ-carboxy prothrombin is superior in detection of hepatocellular carcinoma[J]. Digestion, 2013, 87(2):121-131.
8. El-Serag HB, Kanwal F.α-Fetoprotein in hepatocellular carcinoma surveillance:mend it but do not end it[J]. Clin Gastroenterol Hepatol, 2013, 11(4):441-443.
9. Helaly GF, Abou Shamaa LA. Influence of hepatitis C virus infection on circulating levels of sICAM-1 and VEGF in patients with hepatitis C and hepatocellular carcinoma (HCC) and their role in enhancing detection of HCC[J]. Egypt J Immunol, 2006, 13(1):27-38.
10. Nakano M, Ando E, Kuromatsu R, et al. Recent progress in the management of hepatocellular carcinoma detected during a surveillance program in Japan[J]. Hepatol Res, 2010, 40(10): 989-996.
11. 趙威, 竇科峰, 岳樹強, 等.外周血sICAM-1聯合AFP檢測對原發性肝癌診斷的意義[J].中華實用診斷與治療雜志, 2008, 22(7):481-482.
12. Zhu XW, Gong JP. Expression and role of icam-1 in the occurrence and development of hepatocellular carcinoma[J]. Asian Pac J Cancer Prev, 2013, 14(3):1579-1583.
13. Liu S, Li N, Yu X, et al. Expression of intercellular adhesion molecule 1 by hepatocellular carcinoma stem cells and circulating tumor cells[J]. Gastroenterology, 2013, 144(5):1031-1041.
14. Zhao YJ, Ju Q, Li GC. Tumor markers for hepatocellular carcinoma[J]. Mol Clin Oncol, 2013, 1(4):593-598.
15. Wu J, Zou H, Jiang JT, et al. Clinical application of serum alpha-fetoprotein-IgM complexes on the diagnosis of primary hepatocellular carcinoma in Kazakh and Han populations[J]. Tumori, 2013, 99(4):535-539.
16. Nakazawa T, Hidaka H, Takada J, et al. Early increase inα-fetoprotein for predicting unfavorable clinical outcomes in patients with advanced hepatocellular carcinoma treated with sorafenib[J]. Eur J Gastroenterol Hepatol, 2013, 25(6):683-689.
17. 蘇志良, 趙浩亮, 曹燕, 等.大鼠離體肝臟保存再灌注后肝臟中ICAM-1 mRNA的表達及丹參對其表達的影響[J].中國普外基礎與臨床雜志, 2013, 20(8):932-933.
18. Long EO. ICAM-1:getting a grip on leukocyte adhesion[J]. J Immunol, 2011, 186(9):5021-5023.
19. Xiao X, Mruk DD, Cheng CY. Intercellular adhesion molecules (ICAMs) and spermatogenesis[J]. Hum Reprod Update, 2013, 19(2):167-186.
20. Schmitz V, Sauerbruch T, Raskopf E. Anti-tumoural effects of PlgK1-5 are directly linked to reduced ICAM expression, resulting in hepatoma cell apoptosis[J]. Int J Colorectal Dis, 2012, 27(8): 1029-1038.
21. Jung CW, Song TJ, Lee KO, et al. Characterization of hepatocellular carcinoma cell lines based on cell adhesion molecules[J]. Int J Mol Med, 2012, 29(6):1158-1164.
22. Qin LX, Tang ZY. Recent progress in predictive biomarkers for metastatic recurrence of human hepatocellular carcinoma:a review of the literature[J]. J Cancer Res Clin Oncol, 2004, 130(9): 497-513.
23. Kamezaki S, Kurozawa Y, Iwai N, et al. Serum levels of soluble ICAM-1 and VCAM-1 predict pre-clinical cancer[J]. Eur J Cancer, 2005, 41(15):2355-2359.
24. Sun JJ, Zhou XD, Zhou G, et al. Expression of intercellular adhesive molecule-1 in liver cancer tissues andliver cancer metastasis[J]. World J Gastroenterol, 1998, 4(3):202-205.
25. Sarwar S, Khan AA, Tarique S. Validity of alpha fetoprotein for diagnosis of hepatocellular carcinoma in cirrhosis[J]. J Coll Physicians Surg Pak, 2014, 24(1):18-22.

Previous Article
Activation of Farnesiod X Receptor Inhibited The Growth of Colon Cancer Cells
Next Article
Diagnosis and Treatment on Primary Mass of The Hepatoduodenal Ligament:Report of 16 Cases

CHINESE JOURNAL OF BASES AND CLINICS IN GENERAL SURGERY

Value on Survival Prediction of The Changes of AFP and sICAM-1 Before and after Surgical Treatment of Hepatocellular Carcinoma

Abstract Full text Figures/Tables Video References Cited by

Previous Article

Next Article

Format

Content